Andrew D. Cansfield
Granta Design (United Kingdom)(GB)Heptares Therapeutics (United Kingdom)(GB)
Publications by Year
Research Areas
Cancer-related Molecular Pathways, PI3K/AKT/mTOR signaling in cancer, Neuropeptides and Animal Physiology, Chronic Lymphocytic Leukemia Research, Microtubule and mitosis dynamics
Most-Cited Works
- → A selective inhibitor reveals PI3Kγ dependence of TH17 cell differentiation(2012)143 cited
- → Triazolo[1,5-a]pyrimidines as novel CDK2 inhibitors: Protein structure-guided design and SAR(2005)69 cited
- → Structure-guided design of pyrazolo[1,5-a]pyrimidines as inhibitors of human cyclin-dependent kinase 2(2005)68 cited
- → SAR studies around a series of triazolopyridines as potent and selective PI3Kγ inhibitors(2012)49 cited
- → A Selective Inhibitor Reveals Pi3Kgamma Dependence of T(H)17 Cell Differentiation.(2012)24 cited
- → Structure-Based Drug Discovery of N -(( R )-3-(7-Methyl-1 H -indazol-5-yl)-1-oxo-1-((( S )-1-oxo-3-(piperidin-4-yl)-1-(4-(pyridin-4-yl)piperazin-1-yl)propan-2-yl)amino)propan-2-yl)-2′-oxo-1′,2′-dihydrospiro[piperidine-4,4′-pyrido[2,3- d ][1,3]oxazine]-1-carboxamide (HTL22562): A Calcitonin Gene-Related Peptide Receptor Antagonist for Acute Treatment of Migraine(2020)18 cited
- → Transient treatment with CDK inhibitors eliminates proliferative potential even when their abilities to evoke apoptosis and DNA damage are blocked(2008)17 cited
- → CZ415, a Highly Selective mTOR Inhibitor Showing in Vivo Efficacy in a Collagen Induced Arthritis Model(2016)15 cited
- → Novel Macrocyclic Antagonists of the Calcitonin Gene-Related Peptide Receptor: Design, Realization, and Structural Characterization of Protein–Ligand Complexes(2022)9 cited
- → Structure-based design of peptidomimetic antagonists of p56lck SH2 Domain(2002)7 cited